SCHEMBL4969329

SCHEMBL4969329

Cc1c[nH]c(CCCN)n1

nearest known ligand 0.41

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.41
HRH4 Q9H3N8 6/20 0.41
HRH1 P35367 8/20 0.35
HRH2 P25021 3/20 0.35
TGFBR1 P36897 1/20 0.33
CACNA1H O95180 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
AKT2 P31751 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28545093 0.88
SCHEMBL2037718 0.82 HRH3 (0.42) HRH3
Bromide SCHEMBL27667394 0.80 HRH3 (0.41) HRH3
Water SCHEMBL27852290 0.80 HRH3 (0.41) HRH3
Hydrochloric Acid SCHEMBL14743464 0.80 HRH3 (0.41) HRH3
SCHEMBL5897906 0.80 ALDH1A1 (0.43)
SCHEMBL542826 0.79
SCHEMBL9956114 0.78 ALDH1A1 (0.46)
SCHEMBL83498 0.78 ALDH1A1 (0.46)
SCHEMBL27699982 0.78 ALDH1A1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10350544-B2 Gas treating solutions containing imidazole-amine compounds THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) 2019-07-16 US disclosed
US-20180021723-A1 GAS TREATING SOLUTIONS CONTAINING IMIDAZOLE-AMINE COMPOUNDS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA 2018-01-25 US disclosed
CN-104841406-B A kind of dimethyl aminopropyl imidazoles bonding filter paper solid-phase extraction membrane and its preparation method and application 河南师范大学 2017-10-31 CN disclosed
WO-2016126957-A1 GAS TREATING SOLUTIONS CONTAINING IMIDAZOLE-AMINE COMPOUNDS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) 2016-08-11 WO disclosed
EP-2646423-A1 NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES Galleon Pharmaceuticals, Inc. (US) 2013-10-09 EP disclosed
WO-2012074999-A1 NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS, INC. (US) 2012-06-07 WO disclosed
EP-1973882-A1 PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 2008-10-01 EP disclosed
US-20070213340-A1 Farnesyl protein transferase inhibitors SCHERING CORPORATION 2007-09-13 US disclosed
WO-2007084498-A1 PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 2007-07-26 WO disclosed
US-20060089316-A1 Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof BROWN TRUMAN R 2006-04-27 US disclosed
EP-1175155-A4 METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF FOX CHASE CANCER CT (US) 2005-10-19 EP disclosed
US-6740661-B2 TRICYCLIC IMINE CONTAINING COMPOUNDS HAVING IMIDAZOLE SUBSTITUENT; ANTITUMOR AGENTS SCHERING CORPORATION 2004-05-25 US disclosed
US-6372747-B1 ENZYME INHIBITORS AND ANTICARCINOGENIC AGENTS SCHERING CORPORATION 2002-04-16 US disclosed
EP-1175155-A1 METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF FOX CHASE CANCER CENTER (US) 2002-01-30 EP disclosed
EP-1140902-A1 TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 2001-10-10 EP disclosed
WO-2000062626-A1 METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF FOX CHASE CANCER CENTER (US) 2000-10-26 WO disclosed
WO-2000037459-A1 TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 2000-06-29 WO disclosed
US-5358960-A Stabilization of protein; aging resistance THE ROCKEFELLER UNIVERSITY (US) 1994-10-25 US disclosed
EP-0618907-A1 1-(ARYLALKYL-AMINOALKYL)IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARATION AND USE AS THERAPEUTICAL AGENTS Knoll AG (DE) 1994-10-12 EP disclosed
US-5081131-A Omega-((hetero)alkyl)benz(cd)-indol-2-amines AMERICAN CYANAMID COMPANY (US) 1992-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089316-A1 Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof ALDOA, FBP1, GYS2 HRH3 2705/4885HRH4 3344/4885HRH1 3962/4885
US-20070213340-A1 Farnesyl protein transferase inhibitors FNTB, FNTA, FDPS HRH3 3867/4885HRH4 2441/4885HRH1 4218/4885
US-10350544-B2 Gas treating solutions containing imidazole-amine compounds NISCH, INMT, GMPS HRH3 93/4885HRH4 68/4885HRH1 171/4885
US-20180021723-A1 GAS TREATING SOLUTIONS CONTAINING IMIDAZOLE-AMINE COMPOUNDS NISCH, INMT, GMPS HRH3 93/4885HRH4 68/4885HRH1 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.